Alumis Misses Q2 Revenue as Costs Jump
Alumis (NASDAQ:ALMS), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, released its second-quarter results on August 13, 2025. The company missed consensus GAAP revenue expectations for Q2 2025 and reported sharply higher spending, mainly due to closing and integration costs from its ACELYRIN merger. GAAP revenue was $2.7 million, falling short of the $3.4 million analyst estimate, while expenses soared amid trial acceleration and merger transactions. A one-time accounting gain from the merger propelled net income into positive territory, but the underlying business remained loss-making. The quarter featured mixed results overall, with progress on key clinical programs offset by a miss on top-line expectations and a spike in underlying costs.
Source: Analyst estimates for the quarter provided by FactSet.
Alumis develops therapies that target immune system pathways, aiming to address autoimmune diseases such as psoriasis and systemic lupus erythematosus. Its core pipeline includes oral drug candidates, particularly envudeucitinib, which is a TYK2 inhibitor -- a molecule that blocks a specific protein in the immune process linked to inflammation and autoimmunity.
Source Fool.com
